Efficacy of apremilast in a case of resistant linear IgA bullous disease

Int J Dermatol. 2023 May;62(5):e300-e302. doi: 10.1111/ijd.16548. Epub 2022 Dec 5.

Authors

Vincenzo Maione¹, Luca Bettolini¹, Anna Venturuzzo¹, Francesco Tonon¹, Simonetta Battocchio², Piergiacomo Calzavara-Pinton¹

Affiliations

¹ Department of Dermatology, Spedali Civili, University of Brescia, Brescia, Italy.
² Department of Pathology, Spedali Civili, University of Brescia, Brescia, Italy.

PMID: 36468775
DOI: 10.1111/ijd.16548

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunoglobulin A
Linear IgA Bullous Dermatosis*
Skin Diseases, Vesiculobullous* / drug therapy
Thalidomide / therapeutic use

Substances

apremilast
Thalidomide
Immunoglobulin A